Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Recommendation of “Moderate Buy” from Brokerages

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has earned a consensus recommendation of “Moderate Buy” from the eleven analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $18.30.

Several research analysts have issued reports on YMAB shares. HC Wainwright dropped their target price on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, March 21st. Brookline Capital Management started coverage on Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $17.00 price target on the stock. Bank of America dropped their price objective on Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 5th. Wedbush reiterated an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. Finally, Morgan Stanley reduced their price target on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research report on Wednesday, March 5th.

Insider Buying and Selling at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $5.23, for a total value of $56,536.30. Following the completion of the transaction, the insider now owns 202,721 shares of the company’s stock, valued at $1,060,230.83. This trade represents a 5.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 22.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Y-mAbs Therapeutics during the 3rd quarter worth approximately $44,000. KLP Kapitalforvaltning AS acquired a new position in Y-mAbs Therapeutics during the fourth quarter worth about $46,000. ProShare Advisors LLC purchased a new position in Y-mAbs Therapeutics in the 4th quarter valued at approximately $99,000. Intech Investment Management LLC purchased a new stake in shares of Y-mAbs Therapeutics in the 3rd quarter worth about $133,000. Finally, Wells Fargo & Company MN grew its position in shares of Y-mAbs Therapeutics by 54.1% in the fourth quarter. Wells Fargo & Company MN now owns 17,458 shares of the company’s stock valued at $137,000 after purchasing an additional 6,131 shares during the last quarter. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Trading Down 1.4 %

NASDAQ:YMAB opened at $5.09 on Wednesday. The stock has a fifty day simple moving average of $5.66 and a 200-day simple moving average of $9.65. The company has a market cap of $230.16 million, a price-to-earnings ratio of -9.43 and a beta of 0.65. Y-mAbs Therapeutics has a twelve month low of $4.25 and a twelve month high of $17.78.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its earnings results on Tuesday, March 4th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). The company had revenue of $26.50 million for the quarter, compared to analysts’ expectations of $26.70 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period last year, the business posted ($0.02) earnings per share. As a group, equities research analysts predict that Y-mAbs Therapeutics will post -0.65 EPS for the current fiscal year.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.